Aldeyra Therapeutics Announces Positive Results from Phase 2b Dry Eye Disease Clinical Trial
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of
Tag: SBECD
Melinta Therapeutics to Give New Presentations on Antibiotics Portfolio and Pipeline at IDWeek™ 2018
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, delivered eight
FDA Approves KYPROLIS® (carfilzomib) In Combination With Dexamethasone For Patients With Relapsed Or Refractory Multiple Myeloma
Amgen (NASDAQ:AMGN) recently announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA)
Cyclodextrins in oral formulations – has the time of supergenerics come?
Development of generic formulations with cyclodextrins for oral delivery has been neglected for several decades, since the CD-enabled formulations often
Amgen Submits Supplemental New Drug Application For KYPROLIS® (carfilzomib)
Amgen announced on the 27th August, 2018 the submission of a supplemental New Drug Application (sNDA) to the U.S. Food
Improved method for the preparation of SBECD – In which aspect?
Recently, a new patent application became accessible to the public, WO2018146698 (A1), filed by Biophore India, a DMF holder for the
Video-class on History of Cyclodextrins
Starting from the discovery of cyclodextrins (“cellulosines” at that time) by Villiers in 1891 the history of cyclodextrin research is
AAPS Pharmsci 360 – exhibition and conference combined (4-7th November)
For those, interested in building relationships with industrial partners as well as broadening their knowledge in state-of-the-art academic research, AAPS